Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for somapacitan

  1. Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)

    Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.

    Technology appraisal guidance
    Published
    3 June 2025
    View recommendations

    Sections for TA1066

  2. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]

    Awaiting development [GID-TA11641] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development